News 
Market Data 
Discover
Replies to post #182946 on Anavex Life Sciences Corp (AVXL)
The ACTC is jointly led by:
Paul Stephen Aisen, M.D., director of the ATRI at the Keck School of Medicine of USC, San Diego
Reisa A. Sperling, M.D., director of the Center for Alzheimer Research and Treatment at the Brigham and Women's Hospital, professor of Neurology, Harvard Medical School, Boston
Ronald C. Petersen, M.D., Ph.D., director of the Mayo Clinic Alzheimer's Disease Research Center, professor of Neurology at Mayo Clinic College of Medicine and Science, Rochester, Minnesota
Hoboken, NJ — February 16, 2011 — Anavex Life Sciences Corp. (“Anavex”, AVXL.OB) today announced the appointment of Dr. Paul Aisen to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product pipeline, including its lead compound ANAVEX 2-73, which is being studied for Alzheimer’s disease and is scheduled to enter Phase I clinical trials shortly.
Dr. Aisen is a leading clinician and researcher in Alzheimer’s disease clinical trials and is on the faculty of the University of California, San Diego (UCSD) School of Medicine’s Department of Neurosciences. His primary research interests focus on the development of new strategies for the treatment of Alzheimer’s disease. Since 2007, Dr. Aisen has been Director of the Alzheimer’s Disease Cooperative Study, a consortium funded by the National Institute on Aging (NIA) to develop assessment instruments and conduct clinical trials. Dr. Aisen is Associate Editor of Alzheimer’s Research and Therapy, a major international peer-reviewed journal, and sits on the editorial board of BMC Medicine. He has published more than 180 peer-reviewed papers.
“We are delighted that Dr. Aisen has agreed to join the Anavex Scientific Advisory Board. Dr. Aisen is one of the world’s leading clinical trials research scientists in the field of Alzheimer’s disease. His contributions in the development of ANAVEX 2-73 will be of great importance as we enter clinical trials,” said Dr. Cameron Durrant, Executive Chairman of Anavex.
“I am excited to be assisting Anavex in their endeavors, since my career efforts have been directed towards the development of better therapies for Alzheimer’s disease. We all know that the first drug to treat Alzheimer’s disease came out in 1993 but we are in need of better therapies. I sincerely hope that ANAVEX 2-73, with its unique sigma-1 receptor agonism as well as muscarinic and cholinergic effects, as we have seen in pre-clinical data, will have an impact on the disease process and treatment in patients,” said Dr. Aisen.
NIH/ACTC.....The following guidance for submission for funding by the NIH Alzheimer's Clinical Trials Consortium (ACTC) shows that the process is now showing progress in the first Qtr of 2019.The drug trials accepted for funding should be announced in the next few months, Also contained in this NIA announcement are the locations and investigators in charge 0f the NIH/NIA trial sites. Let's hope we are in the first candidates.
